ARCH Venture Partners — Full Portfolio

908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.

Deep TechDefense TechHardwareMedical DevicesBoston, US

KJKevin J. Knopp, PhD(CEO & Co-founder)CBChristopher Brown(Executive Officer)inKKKevin Knopp(Executive Officer, Director)inJoseph Griffith IV(Executive Officer)

BoardCorey Steffek(Director)

Board seatKCKeith CrandellKHKevin Hrusovsky· per SEC Form D

Co-investorsINIn-Q-TelRARazor's Edge VenturesUTUTECARAramco VenturesARARK Investment ManagementBLBlackRock+4 more

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

DRDavid R. Liu(Founder)inJKJ. Keith Joung(Founder)inFZFeng Zhang(Founder)DRDavid R. Liu, Ph.D.(Founder and Inventor)JKJ. Keith Joung, M.D., Ph.D.(Founder and Inventor)FZFeng Zhang, Ph.D.(Founder and Inventor)

Board seatRNRobert NelsenKBKristina Burow· per SEC Form D

Co-investorsDRDreamers VCEIEight Roads VenturesF-F-Prime CapitalFOForesite CapitalGVGV (Google Ventures)HOHongShan Capital Group+2 more

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

ZDZachary D. Hornby(Executive Officer, Director)inRDRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)JOJessica Oien(Chief Legal Officer and Corporate Secretary)in

BoardBenjamin Cravatt, Ph.D.(Director)

Board seatKBKristina Burow· per SEC Form D

Co-investorsNENextech InvestRARA CapitalWEWellington ManagementALAlexandriaCICity Hill VenturesSESectoral Asset Management+3 more

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHCHelen Collins(Chief Medical Officer)inBHBen Hohl(Chief Financial Officer and Head of Corporate Development)in

Board seatRHRichard Heyman· per SEC Form D · $90M raise · filed Apr 2024

Co-investors5A5AM VenturesOROrbiMedPFPfizer Venture InvestmentsRORoche Venture FundBABay City CapitalJAJanus Henderson Investors+2 more

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

FHFaheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSGSheila Gujrathi, MD(Founder)inBGBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Board seatKBKristina BurowRNRobert Nelsen· per SEC Form D

Co-investorsBABay City CapitalECEcoR1 CapitalFOFoothill VenturesNENew Enterprise Associates (NEA)PIPivotal Life SciencesSASamsara BioCapital+3 more

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)JOJoshua Ofman, MD, MSHS(Chief Executive Officer)inAFAaron Freidin(Executive Officer)inRobert Ragusa(Executive Officer, Director)JCJennifer Cook(Executive Officer, Director)inRichard Klausner(Director)

Board seatRNRobert Nelsen· per SEC Form D

Co-investorsAMAmino CapitalBEBezos ExpeditionsBLBluebird VenturesDEDecheng CapitalDEDentsu VenturesFEFelicis Ventures+13 more

Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

BiotechDeep TechDigital HealthMedical DevicesWatertown, US

PLPaul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)TTTamara Tompkins(Executive Officer)inKari Stefansson(Director)MHMaykin Ho(Director)AHAlaa Halawa(Director)

Board seatRNRobert NelsenKBKristina Burow· per SEC Form D

Co-investorsCACatalio Capital Management, LPF-F-Prime CapitalK2K2 HealthVenturesMEMercury FundPRPremier PartnersSOSoftBank Vision Fund+12 more

Quanterix develops technology for highly sensitive detection of protein biomarkers using non-invasive sample types, aimed at early disease detection and prevention.

BiotechDigital HealthHealthtechMedical DevicesLexington, US

DWDavid Walt(Director)inErnest Orticerio(Executive Officer)Ernest Oriticerio(Executive Officer)MTMasoud Toloue(Former Chief Executive Officer)in

BoardJCJohn Connolly(Director)in

Board seatKCKeith Crandell· per SEC Form D

Co-investorsBABain Capital VenturesFOFoothill VenturesINIn-Q-TelKHKhosla VenturesNONovalis LifeSciences

Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.

BiotechCambridge, US

NMNagesh Mahanthappa(Executive Officer, Director)inTSTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAVAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVSVikas Sinha(Chief Financial Officer)in

Board seatKBKristina Burow· per SEC Form D

Co-investorsAIAisling CapitalECEcoR1 CapitalPOPolaris PartnersTHThe Kraft Group

Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in

Board seatKBKristina Burow· per SEC Form D · $47M raise · filed Jan 2018

Co-investorsSASamsara BioCapitalECEcoR1 CapitalPOPolaris Partners

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

DZDaphne Zohar(Founder, CEO & Board Member)inSPSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)MCMichael Chen(Executive Officer)inLGLana Gladstein(Executive Officer)inALAntony Loebel(Executive Officer)in

Board seatRNRobert Nelsen· per SEC Form D

Co-investorsFOForesite CapitalGEGeneral AtlanticHAHAWKTAILPUPureTech HealthSOSofinnova VenturesCPCPP Investments+3 more

Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.

BiotechDeep TechSemiconductorsSouth San Francisco, US

William Charles Banyai(Executive Officer, Director, Promoter)BJBill James Peck(Executive Officer, Promoter)ELEmily Leproust(Founder)inEmily Leproust, PhD(CEO and Co-Founder of Twist)PFPatrick Finn(President and Chief Operating Officer)inALAdam Laponis(Chief Financial Officer)in

Board seatKCKeith Crandell· per SEC Form D

Co-investors+N+ND Capital3E3E Bioventures CapitalASAsset Management CompanyATATEL VenturesBABay City CapitalBLBlack Opal Ventures+10 more

Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities.

AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US

MDMarianne De Backer(CEO)inHerbert Virgin(Executive Officer)Howard Horn(Executive Officer)inABAlex Bangs(Executive Officer)inMarianne De Backer, M.Sc., Ph.D., MBA(President, Chief Executive Officer and Director)

BoardGSGeorge Scangos(Executive Officer, Director)

Board seatRNRobert NelsenKBKristina BurowVSVicki Sato· per SEC Form D

Co-investorsALAlta PartnersGVGV (Google Ventures)SOSoftBank Vision Fund8V8VCALALTITUDE LIFE SCIENCE VENTURESDCDCVC (Data Collective)+1 more

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases of the central nervous system, including Alzheimer's disease, ALS, and Parkinson's disease.

BiotechHealthtechLexington, US

TCTodd Carter(Executive Officer)inRobin Swartz(Executive Officer)inASAlfred Sandrock(Executive Officer, Director)PPPeter Pfreundschuh(Executive Officer)inNathan Jorgensen(Chief Financial Officer; Principal Financial Officer and Principal Accounting Officer)Steven Hyman(Director)

Board seatGSGeorge Scangos· per SEC Form D · $20M raise · filed Jan 2024

Co-investorsWEWellington ManagementFIFidelity InvestmentsTHThird Rock Ventures

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.

BiotechHealthtechMedical Devices

Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)CBCraig B. Thompson, M.D.(Founder)BGBrian Goff(Chief Executive Officer)in

Co-investorsPOPortage VenturesTHThird Rock VenturesFLFlagship VenturesSASamsara BioCapital

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical DevicesCambridge, US

JMJohn Maraganore(Founder)inPSPhillip Sharp(Founder)David Bartel(Founder)Thomas Tuschl(Founder)Paul Schimmel(Founder)Phillip Zamore(Founder)

Co-investorsATAtlas VentureBLBlackstone Life SciencesCACardinal PartnersINInvivo Capital PartnersALAlexandria

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

MTMarc Tessier-Lavigne(Founder)inAOAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSESteve E. Krognes(Director)inAlexander Schuth(Founder)

Co-investorsECEcoR1 CapitalF-F-Prime CapitalFOForesite CapitalGVGV (Google Ventures)FLFlagship PioneeringFLFlagship Ventures

Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)GYGary Yeung, CFA(Chief Business Officer)in

BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)

PartnerKBKristina Burow· quoted

Co-investorsANAndreessen HorowitzCOColt VenturesEVEvolution VC PartnersFRFrazier Life SciencesLILifeSci Venture PartnersCICity Hill Ventures+1 more

Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.

AI & Machine LearningBiotechDeep TechSomerville, US

GGGevorg Grigoryan(Founder)inMNMichael Nally(Chief Executive Officer)inAvak Kahvejian(Founder)Geoffrey von Maltzahn(Founder)Molly Gibson(Founder)

Co-investorsFLFlagship PioneeringALAlumni VenturesMAMarch Capital PartnersNVNVIDIAALAlaska Permanent Fund CorporationALALTITUDE LIFE SCIENCE VENTURES+4 more

Kardigan develops targeted cardiovascular treatments through a discovery and translational research platform, with a pipeline of late-stage drug candidates aimed at functional cures for cardiovascular disease.

AI & Machine LearningBiotechHealthtechMedical Devices

Tassos Gianakakos(Co-Founder, Chief Executive Officer and Chair)inJay Edelberg, M.D., Ph.D.(Co-founder and Chief Medical Officer)inBob McDowell, Ph.D.(Co-Founder and Scientific Adviser)Leslie Leinwand, Ph.D.(Co-Founder)Beth McNally, M.D., Ph.D.(Co-Founder)

Co-investorsCACatalio Capital Management, LPSESequoia CapitalSESequoia HeritageT.T. Rowe PriceVEVenrock

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

PINGDA REN(Executive Officer)inYLYI LIU(Executive Officer)inTWTroy Wilson(Founder)inTWTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsECEcoR1 CapitalFOForesite CapitalNENextech InvestOUOUP (Osage University Partners)

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

CHCharles Homcy(Director)JCJason Coloma(Chief Executive Officer)in

Co-investorsANAndreessen HorowitzFOForesite CapitalFRFrazier Life SciencesGVGV (Google Ventures)HEHercules Capital, Inc.ALAlexandria+9 more

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsCACatalio Capital Management, LPFOForesite CapitalFRFrazier Life SciencesGEGeneral CatalystGVGV (Google Ventures)HBHBM Healthcare Investments+9 more

PerkinElmer is a scientific instrument and technology company that provides analytical tools and services for research, diagnostics, and life sciences applications.

BiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesWaltham, US

Richard Scott PerkinJames M. Mock(Executive Officer)AOAndrew Okun(Executive Officer)inJoel S. Goldberg(Executive Officer)Tajinder Vohra(Executive Officer)inPRPrahlad R. Singh(President and Chief Executive Officer)in

Co-investorsAMAmpersand

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.

BiotechDeep TechHealthtechMedical DevicesFramingham, US

Anand Varadan(Director)inRichard Batycky(Director)Peter Ludlum(Interim Chief Executive Officer)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)

BoardRichard Conley(Director)

Co-investors5A5AM VenturesALALTITUDE LIFE SCIENCE VENTURESPOPolaris Partners

Rapport is a biopharmaceutical company developing novel therapeutics.

BiotechHealthtechMedical Devices

ACAbe Ceesay(President)CGCheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)Steven Paul David Bredt(Founder)

Co-investorsSOSofinnova VenturesCACapital GroupJOJohnson & Johnson Innovation – JJDCTHThird Rock Ventures

Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease.

BiotechDigital HealthHealthtechMedical DevicesCary, US

SNShahid Nimjee(Co-founder, Chief Scientific Officer and Stroke Clinical Lead)inBruce Sullenger(Co-founder)JOJulia Owens(Executive Officer, Director, Promoter)inRSRichard Shea(Executive Officer, Director, Promoter)in

BoardHannah Chang(Director)AAAiden Aceves(Director)in

Board seatSGSteve Gillis· per SEC Form D

Co-investorsINInsight PartnersBRBroadview VenturesMEMedblueSOSolas BioVenturesPLPlatanus VenturesRERev1 Ventures+1 more

Cytrellis develops medical device technologies focused on aesthetic and reconstructive treatments, with expertise spanning dermatology, plastic surgery, and wound healing applications.

BiotechHealthtechMedical DevicesWoburn, US

Rox Anderson, MD(Founder, Medical / Technology Advisor)William G. Austen, Jr. MD(Founder, Medical / Technology Advisor)Doug Levinson, PhD(Founder)DDDenise Dajles, PhD(President & CEO)JMJohn McDonough(Executive Officer, Director)inDSDavid Stone(Executive Officer)in

Board seatKCKeith Crandell· per SEC Form D

Co-investorsSASands Capital Ventures

IngredientWerks is a molecular farming company that engineers plants to produce plant-based proteins and ingredients for the alternative protein market.

AgTechBiotechFoodTechWoburn, US

MPMatt Plavan(Chief Executive Officer)inMichael Raab(R&D Lead)JSJeremy Schley-Johnson(Vice President)inSteve Snyder(Director)James Schultz(Director)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsOPOpen PrairieCUCultivian Sandbox VenturesSASandbox Industries

Skylark Bio develops precision-targeted, locally delivered AAV gene therapies for single-gene disorders, starting with genetic causes of hearing loss and extending toward central nervous system conditions.

BiotechDeep TechLongevityMedical DevicesCambridge, US

Giampiero De Luca(Director)Jodi A. Cook(President & CEO)Will McLean(Executive Officer)Shawn Harriman(Chief Development Officer, Head of Translational Sciences)Casey Maguire(Scientific Co-founder & Consultant)Nilay Thakar(Co-founder & Head of Business Development)

Board seatSGSteve Gillis· per SEC Form D

Co-investorsARArkin Capital

Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US

GEGeorge Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXZXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)RCRob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in

Board seatKCKeith Crandell· per SEC Form D

Co-investorsNONorthpond Ventures6 6 Dimensions CapitalALAlly Bridge GroupAPApplied VenturesKIKilonova CapitalPUPura Vida Investments+3 more

Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.

AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US

GEGeorge Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inRobert Carson(Executive Officer, Director)TLTerry Lo(Director)inSeth Benson(Executive Officer)inSimona Levi(Executive Officer)in

Board seatKCKeith Crandell· per SEC Form D

Co-investorsM M VenturesNONorthpond VenturesILIllumina VenturesNONovalis LifeSciences

Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US

FZFeng Zhang, Ph.D.(Scientific Founder & Board Observer)AAAkin Akinc, Ph.D.(Chief Executive Officer & Board Director)Akin Akinc(Founder)Feng Zhang(Founder)Feng Zhang Akin Akinc(Founder)John Maraganore(Founder)

Co-investorsLULux CapitalF-F-Prime CapitalGVGV (Google Ventures)JDJDRF T1D FundALAltitude Ventures Management, LlcNENewpath Partners

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

ABAndrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inABANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)DMDamien McDevitt(President and Chief Executive Officer)inDMDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)

Co-investorsLILifeforce CapitalOROrbiMedDODomain AssociatesEDEDB InvestmentsSESection 32FRFrazier Life Sciences+10 more

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

RYRichard Young, Ph.D.(Director)inAHAnthony Hyman, Ph.D.(Director)THTony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)

Co-investorsECEcoR1 CapitalGEGeneral CatalystSASamsara BioCapital6 6 Dimensions CapitalINInnovation EndeavorsLELeaps by Bayer+6 more

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.

BiotechDeep TechHealthtechBurlington, MA, US

JRJay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)AOArthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)

Co-investorsATAtlas VentureSASanofi Ventures5A5AM Ventures

Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.

AI & Machine LearningBiotechMedical DevicesBoston, US

Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)MRMichael Rosbash, PhD(Founder & Advisor)RSRicha Saxena, PhD(Founder & Advisor)SSStuart Schreiber, PhD(Founder & Advisor)BSBrian Safina(President & Chief Executive Officer)in

Co-investorsNENewpath PartnersTATaiho Ventures, LLC

Moleculent develops biological discovery and disease understanding tools for scientists.

AI & Machine LearningBiotechDeep TechSolna, SE

FRFredrik Roos(CTO & Co-founder)in

Co-investorsEIEIR Ventures

Paradigm Health provides technology and services that integrate with healthcare provider organizations to improve the clinical trial process.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSaaSColumbus, US

KTKent Thoelke(Founder)inJonathan Hirsch(Chief Strategy and Growth Officer)JTJay Trepanier(Chief Financial Officer)inElijah Meerson(Chief Technology Officer)inMLMichelle Lee(Chief Operating Officer)in

Co-investorsGEGeneral CatalystGVGV (Google Ventures)LULux CapitalF-F-Prime CapitalJOJobsOhio VenturesMAMagnetic Ventures+2 more

Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.

BiotechHealthtechLongevityLos Angeles, US

Heather Christofk(Executive Officer)WLWilliam Lowry(PhD)inCWChristina Weng(Chief Medical Officer)inNWNathan Wheeler(Chief Operating Officer)in

BoardCFCathy Friedman(Director)inDGDaniel Gil(CEO)

Co-investorsGVGV (Google Ventures)HAHAWKTAILVIVisionary VenturesYKYK Bioventures

Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.

BiotechDeep TechHealthtechMedical Devices

MMMichal Minczuk(Co-Founder)inGMGabriel Martinez(Chief Scientific Officer & Co-Founder)CGClaes Gustafsson(Co-Founder)MFMaria Falkenberg(Co-Founder)NLNils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)

Co-investorsCACambridge Innovation CapitalEIEIR VenturesANAngelini VenturesGVGV (Google Ventures)HEHealthCapINInvus+2 more

RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.

BiotechDigital HealthMedical DevicesBasel, CH

BRBotond Roska(Researcher (M.D., Ph.D.))BGBence György(IOB Assistant Professor & Head of Clinical Translation)inKHKatherine High(CEO)in

Co-investorsNONovartis Venture FundBIBioGeneration VenturesF-F-Prime CapitalGVGV (Google Ventures)

Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.

BiotechMedical Devices

TETony Estrada(President & Chief Executive Officer; co-founder)in

Co-investorsF-F-Prime CapitalBABain Capital Life SciencesDIDigitalis VenturesFOForbionMUMubadala Capital

AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.

AI & Machine LearningBiotechDeep TechHealthtechStanford, US

TSThorsten Stafforst(Chairman of the Board of Directors)inKEKris ElveruminTBTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in

BoardRodger Novak(Chair)in

Co-investors+N+ND CapitalFOForbionVEVenrockFAFast Track InitiativeLILifelinkNENextech Invest+3 more

Fabless US semiconductor company making ultralow-power non-volatile memory, ASICs and IoT embedded systems; acquired by Dialog in 2020.

Sunnyvale, US

NDNarbeh Derhacobian(Executive Officer, Director)inRon Shelton(Executive Officer)in

BoardMatt Boyle(Director)AAAlexei Andreev(Director)inBarry Cox(Director)

Board seatKCKeith Crandell· per SEC Form D · $12.5M raise · filed Sep 2015

US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.

AgTechResearch Triangle Park, US

Scott Uknes(Manager)inEWEric Ward(Manager)PSPaul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)

BoardThomas Dietz(Manager)

Board seatKBKristina Burow· per SEC Form D

Co-investorsALAliment CapitalBLBlue Horizon CorporationPOPontifax AgTechBIBill & Melinda Gates FoundationLELeaps by BayerNONovalis LifeSciences+1 more

Agrivida develops enzyme technology for animal feed and nutrition, improving efficiency in poultry, swine, and other livestock production.

AgTechBiotechFoodTechMassachusetts, US

RMR. Michael Raab(Executive Officer)Daniel Meagher(Executive Officer, Director)JSJeremy Schley Johnson(Executive Officer)

BoardRob Johnson(Director)Mark Austin(Director)Robert Bucklin(Director)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsMIMiddleland CapitalPRPresidio VenturesCUCultivian Sandbox VenturesDADag VenturesKLKleiner Perkins

Alzheon is a clinical-stage biopharmaceutical company developing oral small-molecule drugs for Alzheimer's disease and other neurodegenerative disorders, with a Phase 3 program for its lead compound valiltramiprosate (ALZ-801).

BiotechDeep TechHealthtechFramingham, US

MTMartin Tolar, M.D., Ph.D.(President and Chief Executive Officer)MTMartin Tolar(Founder, President & CEO)inGEGlenn E. Pauly(Chief Commercial Officer)inSASusan Abushakra, M.D.(Chief Medical Officer)inJHJohn Hey, Ph.D.(Chief Scientific Officer)Kenneth A. Mace(Treasurer and Chief Financial Officer)

Board seatScott Minick· per SEC Form D · filed Feb 2015

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.

BiotechDigital HealthMedical DevicesCambridge, US

DADAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FZFENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)DWDavid Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)

Board seatKCKeith Crandell· per SEC Form D

Co-investorsILIllumina VenturesONOno Venture Investment, Inc.TCTCG CrossoverALAlly Bridge GroupJAJanus Henderson InvestorsRERevelation Partners+4 more

Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

BiotechChapel Hill, US

RWRobin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Founder)in

BoardBenjamin Gomez(Director)AKAdam Koppel(Director)inMichael E. Bozik(Director)

Board seatPBPaul Berns· per SEC Form D

Co-investorsBABain Capital Life SciencesGVGV (Google Ventures)SOSolas BioVenturesVIViking GlobalACAccess BiotechnologyMAMaverick Capital+3 more

Seattle 'scientific wellness' startup that paired genetic, blood and microbiome testing with health coaching; closed in 2019.

HealthtechSeattle, US

Nathan Price(Director)Clayton Lewis(Executive Officer, Director)

BoardTim Kilgallon(Director)

Board seatRNRobert Nelsen· per SEC Form D · $30M raise · filed Jun 2017

Co-investorsCOCorewell Health VenturesPOPolaris Partners

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.

BiotechDeep TechMedical DevicesSan Diego, US

KFKevin Finney(Chairman, President and CEO)inJBJohn Borkholder(Executive Officer)in

BoardTCThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)

Board seatKBKristina Burow· per SEC Form D

Co-investorsCACanaan PartnersMOMonograph Capital PartnersPFPfizer Venture InvestmentsSASamsara BioCapitalINInsight PartnersNENewpath Partners

Cooledge designs and manufactures specialized lighting solutions including LED luminaires, tunable white products, and architectural lighting systems for commercial and industrial applications.

Advanced ManufacturingCleantechConstruction TechHardwareRichmond, US

BillCalvin Wade Sheen(Executive Officer, Director)

BoardWilliam Sims(Director)Kirk A. Washington(Director)GCGeoff Catherwood(Director)inThomas Bilbrough(Director)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsSASaints CapitalYAYaletown PartnersBDBDC Venture Capital

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

BoardGMGeorge M. Church(Director)

Board seatSteven Gillis· per SEC Form D

Co-investorsALAlta PartnersCACatalio Capital Management, LPHBHBM Healthcare InvestmentsHBHBM PartnersKHKhosla VenturesLILifeSci Venture Partners+12 more

Elephas develops elive, a live-tissue platform technology that predicts immunotherapy response in cancer patients by measuring real-time immune activity in intact tumor tissue.

BiotechDigital HealthHealthtechMedical DevicesMadison, US

Jonathan Oliner(Executive Officer)inMAManeesh Arora(Founder)inMichelle B. Arora(Director)Terrence P. Brady(Executive Officer)

Board seatPBPaul Berns· per SEC Form D

Co-investorsNONorthpond VenturesSASands Capital Ventures

Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.

BiotechSeattle, US

MRMark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)SHStephen Hill(Executive Officer, Director)

BoardPHPaulina Hill(Director)in

Board seatSteven Gillis· per SEC Form D

Co-investorsOUOUP (Osage University Partners)POPolaris Partners

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

DKDaphne Koller(Founder)inDVDuane Valz(General Counsel)inMRMary Rozenman(Chief Financial Officer)in

BoardVPVijay Pande(Director)in

Board seatRNRobert Nelsen· per SEC Form D

Co-investorsANAndreessen HorowitzDEDeviation CapitalFOForesite CapitalGVGV (Google Ventures)HOHOF CapitalSOSoftBank Vision Fund+9 more

Seattle-based cancer immunotherapy company developing CAR-T and TCR cell therapies; acquired by Celgene, now part of Bristol-Myers Squibb.

BiotechSeattle, US

Hans Bishop(Executive Officer, Director, Promoter)Richard Klausner(Director, Promoter)Bernard J. Cassidy(Executive Officer)Robert Azelby(Executive Officer)Sunil Agarwal(Executive Officer)Rupert Vessey(Director)

Board seatRNRobert Nelsen· per SEC Form D

Co-investorsBEBezos ExpeditionsRIRidgeback CapitalALAlaska Permanent Fund CorporationCRCrestline InvestorsVEVenrock

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardANAmir Nashat(Director)in

Board seatKBKristina BurowRHRichard Heyman· per SEC Form D

Co-investorsAGage1ECEcoR1 CapitalLALAVLILifeSci Venture PartnersLILilly Asia VenturesNENew Enterprise Associates (NEA)+8 more

Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.

BiotechHealthtechMedical DevicesNew York, US

CAClive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)Clive Meanwell(Founder)

Board seatKBKristina BurowPBPaul Berns· per SEC Form D

Co-investorsALAlpha Wave GlobalF-F-Prime CapitalGVGV (Google Ventures)RARA CapitalSOSoftBank Vision FundVIViking Global+5 more

Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.

AI & Machine LearningHealthtechMedical DevicesSan Diego, US

MCMark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)Mark McKenna(Founder)

Board seatKBKristina BurowPBPaul Berns· per SEC Form D

Co-investorsAQAquiline Technology GrowthOROrbiMedSASanofi VenturesINInvusPOPoint72VEVenrock Healthcare Capital Partners

Nanosys develops Quantum Dot technology and materials, providing samples, R&D collaboration, and scaled production for partners building display and other advanced-material products.

Advanced ManufacturingDeep TechHardwareNew MaterialsSemiconductorsMilpitas, US

JHJason Hartlove(Executive Officer, Director)inJCJian Chen(Executive Officer)inRKRussell Kempt(Executive Officer)inNoland Granberry(Executive Officer)inDr. Martin Devenney(Co Chief Executive Officer and Assistant Secretary)Dr. Hirokazu Sasaki(President & CEO and Treasurer, Shoei Electronic Materials, Inc. • Operating Officer & Division Manager QD Business Dept., Shoei Chemical, Inc.)

Board seatKCKeith Crandell· per SEC Form D · $10M raise · filed Mar 2015

Co-investorsARArcher Capital GroupARArcher Venture CapitalPRProspect Venture PartnersSTStructural CapitalTETEL Venture Capital, Inc.VEVenrock+4 more

RNA therapeutics company with a chip-based mRNA manufacturing platform; acquired by Medici Therapeutics in November 2025.

BiotechEmeryville, US

Igor Khandros(Executive Officer, Director)

Board seatRNRobert Nelsen· per SEC Form D

Co-investors+N+ND CapitalBLBluebird VenturesBYByers CapitalCRCraft VenturesFOFounders FundPAParadigm+2 more

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

BiotechHouston, US

ABAlice Bexon(Executive Officer)inCJClifford J. Stocks(Director, Executive Officer)inKDKamal D. Puri(Executive Officer)inCRChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)

Board seatSteven Gillis· per SEC Form D

Co-investors3B3B Future Health FundCACanaan PartnersGRGreatPoint VenturesRIRiverVest Venture PartnersALAlexandriaBEBering Capital+5 more

Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.

BiotechHealthtechMedical DevicesRedwood City, US

IWIrv Weissman(Cofounder, Scientific Advisor, Board Director)RMRavi Majeti(Cofounder, Scientific Advisor, Board Observer)ABAmira Barkal(Principal Founder, Scientific Advisor, Board Director)inRMRoy Maute(Cofounder & Chief Executive Officer)in

BoardJVJacob Vogelstein(Director)

Board seatSteven Gillis· per SEC Form D

Co-investorsCACatalio Capital Management, LPALAlexandriaCACatalio Capital Management

Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.

BiotechHealthtechSeattle, US

CTCHRISTOPHER TOOMBS(Executive Officer)inLRLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)

BoardThong Le(Executive Officer, Director, Promoter)

Board seatSteven Gillis· per SEC Form D

Co-investorsACACCELERATOR LIFE SCIENCE PARTNERSALAlexandriaWRWRF Capital

Ramona Optics builds parallelized multi-camera array microscope systems for imaging and analyzing small model organisms and cell cultures in multi-well plates.

BiotechDeep TechHardwareDurham, US

RHRoarke Horstmeyer(Director)inMark Harfouche(Executive Officer, Director)inRobert Horstmeyer(Director)Margaret Aery(Executive Officer)inGregor Horstmeyer(Executive Officer, Director)

Board seatSKSean KendallPWPatrick Weiss· per SEC Form D · $31M raise · filed Mar 2026

Co-investorsTHThe E14 Fund

Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.

Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US

William S. Marth(Chief Executive Officer)William S. Marth, RPh., MBA(President & CEO)

Board seatRNRobert Nelsen· per SEC Form D

Co-investors8V8VCCACatalio Capital Management, LPGLGlobal Health Investment CorporationGVGV (Google Ventures)KOKoch Disruptive TechnologiesLULux Capital+14 more

Rezo maps disease networks to find insights into disease biology for drug discovery.

AI & Machine LearningBiotechDeep TechSan Francisco, US

NKNevan Krogan(Co-Founder)inSourav Bandyopadhyay(Co-Founder)inNBNorbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)GSGeorge Scangos(Co-Founder)Kevan Shokat(Co-Founder)

Board seatGSGeorge Scangos· per SEC Form D · $80.1M raise · filed Aug 2025

Co-investorsANAndreessen HorowitzNONorwest Venture PartnersHAHAWKTAILSRSR One Capital ManagementVAValkyrie Ventures Management, LlcSVSV Angel

Rippl delivers evidence-based dementia care through a combination of technology and human support for people living with dementia and their families.

Digital HealthHealthtechSeattle, US

KEKris Engskov(Co-founder & CEO)inRNRobert Nelsen(Co-Founder & Board Chair)Paul Engskov(Executive Officer, Director)

BoardHMHolly Maloney(Director)inIyah Romm(Director)Ryan Watts(Director)

Board seatRNRobert Nelsen· per SEC Form D

Co-investors181843 CapitalCICity LightEQEquitage Ventures, L.L.C.F-F-Prime CapitalGEGeneral CatalystGVGV (Google Ventures)+2 more

Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.

BiotechHealthtechMedical DevicesSeattle, US

RMRichard Mulligan(Director)inHBHans Bishop(Founder)SHSteve Harr(Founder)JJJames J. MacDonald(Executive Officer)NHNathan Hardy(Executive Officer)

BoardGVGeoffrey von Maltzahn(Director)in

Board seatRNRobert Nelsen· per SEC Form D

Co-investorsAMAmerican Family VenturesCACatalytic Impact FoundationF-F-Prime CapitalFLFlagship PioneeringGVGV (Google Ventures)INInnovating Capital+8 more

Semprius was a Durham, NC developer of micro-transfer-printed high-concentration photovoltaic solar modules, spun out of the University of Illinois.

Durham, US

JOHN ROGERS(Executive Officer, Director)JOSEPH CARR(Executive Officer, Director)HELENA YEE(Executive Officer)JACK BARRY(Executive Officer)

BoardGREG WOLF(Director)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsINIn-Q-TelAPApplied VenturesHGHG VenturesILIllinois Ventures

Seranova is a biotech company that combines REAP autoantibody profiling with clinically linked patient cohorts to identify naturally occurring protective autoantibodies against specific extracellular targets and translate those protective associations into therapeutic hypotheses.

AI & Machine LearningBiotechDeep TechNew Haven, US

ARAaron Ring(Manager)inBeatrice McQueen(Executive Officer)

BoardJim Tananbaum(Manager)

Board seatSOSabah Oney· per SEC Form D · $10M raise · filed Feb 2024

Co-investorsAXAxial VCFOForesite Capital

Westlake Village dermatology company developing late-stage topical and photoparticle skin treatments; assets sold to Sebacia in 2020.

BiotechWeslake Village, US

Frederick C. Beddingfield III(Executive Officer, Director)THTodd Harris(Director, Executive Officer)inDSDiane Stroehmann(Executive Officer)inPFPaul F. Lizzul(Executive Officer)inRPRic Peterson(Executive Officer)inTimothy K. Andrews(Executive Officer)

Board seatRNRobert NelsenKBKristina Burow· per SEC Form D · $40.5M raise · filed May 2017

San Francisco catalyst company that converted natural gas to ethylene and fuels; acquired by McDermott in 2019.

San Francisco, US

Edward J Dineen(Executive Officer, Director)Jeffrey P. Wood(Executive Officer)

BoardMichel Maloof(Director)Leighton Read(Director)Paula Reynolds(Director)

Board seatCBClinton Bybee· per SEC Form D · $25.7M raise · filed Jan 2016

Co-investorsLULux CapitalPRPresidio VenturesKLKleiner PerkinsSASaudi Aramco Energy Ventures

Slingshot Biosciences makes synthetic cell mimics used as standardized reference controls for flow cytometry and cell-based assays.

Emeryville, US

JKJeff Kim(Founder)inAdam Wieschhaus(Director)Ronald J. Silberman(Director)

Board seatCRCorey RitterPWPatrick Weiss· per SEC Form D

Co-investorsANAnterra CapitalNONorthpond Ventures

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US

KGKenneth Greenberg(Co-Founder, President & CEO)in

Board seatSteven Gillis· per SEC Form D

Co-investorsVIVida VenturesLELeaps by BayerFOFoothill VenturesILIllumina VenturesMEMedical Excellence CapitalVIVivo Capital+8 more

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

BiotechCambridge, US

Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)

Board seatRNRobert NelsenVSVicki Sato· per SEC Form D

Co-investorsAIAisling CapitalQUQuan CapitalALAlexandriaALAlly Bridge GroupBABain CapitalBABain Capital Life Sciences+11 more

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.

AI & Machine LearningBiotechHealthtechMedical DevicesWatertown, US

JHJoshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)inJosh Bilenker Jeff Engelman(Founder)

BoardAli Satvat(Director)

Board seatKBKristina Burow· per SEC Form D

Co-investorsAIAisling CapitalGVGV (Google Ventures)OROrbiMedARARC VENTURESCACasdin CapitalEXExor+3 more

Unity Biotechnology was a biotechnology company that is no longer operating.

BiotechBrisbane, US

NENathaniel E. David(Executive Officer, Director)inDMDan Marquess(Executive Officer)inKLKeith Leonard(Executive Officer, Director)inTTTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in

Board seatRNRobert NelsenKBKristina Burow· per SEC Form D

Co-investorsAGage1ALAlumni VenturesCYCycad Group LLCECEcoR1 CapitalKHKhosla VenturesVEVenrock+6 more

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

BCBen Cravatt(Scientific Founder)PBPhil Baran(Scientific Founder)JYJin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in

BoardJPJohn Park(Executive Officer)JCJohn Clarke(Executive Officer, Director)in

Board seatKBKristina BurowRHRichard Heyman· per SEC Form D

Co-investorsAVAvoro Capital AdvisorsCACardinal PartnersNENextech InvestSOSoftBank Vision FundALAlexandriaALALTITUDE LIFE SCIENCE VENTURES+4 more

Company producing world's first multi-material 3D printer capable of printing functional features with variable material properties.

Somerville, US

JAJennifer A. Lewis(Executive Officer, Director)

BoardJMJiong Ma(Director)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsBRBraemar Energy VenturesINIn-Q-TelOUOUP (Osage University Partners)

Subsea and terrestrial optical transport supplier whose assets, rescued by H.I.G. in 2017, are being bought by Prysmian and Fincantieri.

Allen, US

Keith Henderson(Executive Officer)inLes Barkley(Executive Officer)inPaul Colan(Executive Officer)inJon Hopper(Executive Officer, Director)inGary Otake(Executive Officer)inHerve Fevrier(Executive Officer)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsARAristos VenturesNENew Enterprise Associates (NEA)WEWellcome Trust

Xtremity makes the XtremityTT, a thermoformable definitive prosthetic socket system built from an injection-molded, carbon-reinforced polymer preform that clinicians can heat, form, and assemble in about an hour and re-adjust via spot-heating.

HardwareHealthtechMedical DevicesNew MaterialsAspen, US

MJMark Joseph(Inventor/Product Designer, company founder)Miguelangel Sosa(Executive Officer, Director)Amy Hill(Executive Officer)Scott Ward(Executive Officer)Maynard Carkhuff(President & CEO)

Board seatRNRobert Nelsen· per SEC Form D · $15M raise · filed Jun 2021

Co-investorsDEDecheng CapitalRSRsquared

Accompany was a relationship intelligence and business insights platform that has been acquired by Cisco and integrated into their collaboration products suite.

Enterprise SoftwareSaaS

RMRyan McDonough(Founder)inAmy Chang(Founder)Matthias Ruhl(Founder)

Co-investorsCOCowboy VenturesCRCRV (Charles River Ventures)VIVista Venture PartnersICICONIQ CapitalIVIVP (Institutional Venture Partners)VEVenrock

Bethesda-based provider of in-home and virtual primary, behavioral and social care for low-income patients with complex needs.

HealthtechBethesda, US

RRRahul Rajkumar(Founder)in

BoardBryan Roberts(Director)Robert Kocher(Director)Stephanie Lovell(Director)Vivian Riefberg(Director)

Co-investorsIVIVP (Institutional Venture Partners)VEVenrock

Ahura Scientific offers portable analytical instruments (under the Thermo Scientific brand) that use XRF, NIR, Raman, and FTIR technologies for rapid chemical identification and material verification in field environments.

Advanced ManufacturingDeep TechHardware

Co-investorsCACastile VenturesFUFuse Capital

Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsSRSR One Capital ManagementIPIP GroupLULundbeckfonden VenturesWEWestlake Village BioPartners

Aledade is an accountable care organization (ACO) partner that works with primary care organizations to improve patient outcomes and healthcare quality.

Enterprise SoftwareHealthtechBethesda, US

BSBijan Salehizadeh(Co-founder)inFMFarzad Mostashari(Founder)inMKMat Kendall(Founder)in

BoardRKRobert Kocher(Director)in

Co-investorsACActivate Venture PartnersECEcho Health VenturesGVGV (Google Ventures)INIntrepid Growth PartnersIVIVP (Institutional Venture Partners)LILightspeed Venture Partners+11 more

Altos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.

BiotechDeep TechLongevityBay Area, US

Richard Murray(CEO and Founder)Shinya Yamanaka(Founder)HBHal Barron(CEO and Founder)inRKRichard Klausner(Founder)HBHans Bishop(Founder)JCJuan Carlos Izpisua Belmonte(Founder)in

Co-investors8V8VCGEGeneral CatalystLULuma GroupALAltitude Ventures Management, Llc

Boulder-based biopharmaceutical company developing targeted small molecule cancer drugs; acquired by Pfizer in 2019.

Co-investorsFRFrazier Life SciencesRIRidgeback CapitalBOBoulder Ventures

Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.

BiotechHealthtechMedical DevicesSouth San Francisco, US

KDKen Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)Alexander Marson(Founder)Kole Roybal(Founder)

Co-investorsHIHitachi VenturesKLKleiner PerkinsLULuma GroupOUOUP (Osage University Partners)SOSoftBank Vision FundWEWestlake Village BioPartners+4 more

Co-investorsALAlta PartnersDCDC Investment PartnersLOLongwood FundNENextech InvestPAPathway to CuresATAtlas Venture+6 more

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.

BiotechDeep TechHealthtechMedical Devices

DMDr Mark Kotter(Founder)POPrzemek Obloj(CEO)inEPEmma Pepperell(CEO)inMark Kotter(Founder)

Co-investorsFOForesite CapitalBLBlueYard CapitalDYDynamk CapitalGOGood AI CapitalHAHarmonix FundHAHAWKTAIL+7 more

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

BiotechLongevityMedical DevicesCambridge, US

DMDavid Meek(Chief Executive Officer)inBRBrian Riley(President & Chief Technical Officer)inJLJoanne Lager(Chief Medical Officer)inWDWendy DiCicco(Chief Financial Officer)inACAdrian Chaisson(Chief of Staff)inJCJason Cole(Executive Officer)

Co-investorsEAEaston CapitalRARA CapitalSASanofi VenturesTHThink+ Ventures Management, LlcWAWakestream VenturesFOForbion+1 more

Hong Kong-listed (2137.HK) biotech founded in 2018 developing infectious disease therapies, led by hepatitis B functional-cure programs.

ZHZhi Hong(Founder)in

Co-investors6 6 Dimensions CapitalBLBlue Pool CapitalBOBoyu CapitalSESequoia Capital

Carrick Therapeutics is a biopharmaceutical company with a leadership team experienced in oncology drug development and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

TPTimothy Pearson(CEO)ABAsh Bahl(CSO)inJHJenny Horsfield(CBO)inSMStuart McIntosh(CMO)inDSDavid Sutherland(VP Finance & Controller)

Co-investorsB B Capital GroupB4B4 CapitalCACambridge Innovation CapitalGVGV (Google Ventures)LILightstone VenturesRERevelation Partners+2 more

BiotechNewton Centre, US

Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)

BoardScott Minick(Director)inTTTodd T. Foley(Director)inVincent Miles(Director)AKAnsbert K. Gadicke(Director)in

Co-investorsHEHEALTHCARE ROYALTY PARTNERSSOSofinnova VenturesABAbingworthMPMPM BioImpact

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.

BiotechMedical DevicesCambridge, US

MKMark Keating, MD(Co-founder)KNKotaro Nakanishi, PhD(Co-founder)YTYukihide Tomari, PhD(Co-founder)PZPhillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in

Co-investorsANAN Venture PartnersSOSofinnova VenturesVIViking GlobalALAltitude Ventures Management, LlcCACasdin CapitalFIFidelity Investments+5 more

Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.

BiotechSeattle, US

DWDoug Williams(Executive Officer, Director)in

BoardNANoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)

Co-investorsECEcoR1 CapitalALAlexandriaFIFidelity InvestmentsFLFlagship PioneeringQAQatar Investment Authority

Countable Labs (formerly Enumerix) develops Countable PCR, a DNA quantification technology that provides absolute target counts at single-molecule resolution as an alternative to qPCR, digital PCR, and NGS.

BiotechDeep TechHealthtechMedical DevicesPalo Alto, US

SFStephen Fodor(Co-Founder & Board Director)ACAri Chaney(Co-Founder & Board Director)inCFChristina Fan(Co-founder + CTO)inGPGiovanna Prout(Chief Executive Officer)in

Co-investorsF-F-Prime CapitalPRPrimer Ventures

Hong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.

Co-investors6 6 Dimensions CapitalBOBoyu CapitalGIGICHIHillhouse CapitalSESequoia CapitalWUWuXi Healthcare Ventures

Curie.Bio is a biotech venture firm pairing seed capital with in-house drug discovery support for therapeutics founders.

ZWZach Weinberg(Founder)inAlexis Borisy(Founder)Christoph Lengauer(Founder)

Co-investorsALAlleyCorpBOBoxGroupDNDNA CapitalF-F-Prime CapitalGVGV (Google Ventures)LILightstone Ventures+5 more

deCODE analyzes and interprets the human genome to identify genetic risk factors for common diseases including cardiovascular disease and cancer.

AI & Machine LearningBiotechDeep TechReykjavik, IS

KSKári Stefánsson(Founder)in

Co-investorsATAtlas Venture

Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.

CleantechClimate TechDeep TechNew Materials

CNChiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in

Co-investorsIMImpact Ventures Management Pty LtdPAPacific Channel3E3E Bioventures CapitalECEcoR1 CapitalGEGeneral CatalystLELeaps by Bayer+3 more

Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.

BiotechDeep TechMedical Devices

LJLex Johnson(Co-Founder and Chief Platform Officer)inRLRay Liu(Co-founder and Head of Synthetic Biology)JMJeff Marrazzo(Founder)inSOSabah Oney(Chief Executive Officer)in

Co-investorsALAlexandriaSTStanford University

eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.

BiotechDeep TechMedical Devices

MCMike Curtis, Ph.D.(President & Chief Executive Officer)George M. Church(Founder)Luhan Yang(Founder)

Co-investorsALAlta PartnersALAltium CapitalEIEisai Innovation, Inc.FRFresenius Medical Care VenturesKHKhosla VenturesLULux Capital

Encoded develops gene therapies for neurological disorders through an integrated platform approach.

BiotechSouth San Francisco, US

STStephanie Tagliatela(Founder)inKRKartik Ramamoorthi, Ph.D.(Co-founder, Chief Executive Officer & Board Member)Kartik Ramamoorthi(Founder)

Co-investorsBIBioBritGVGV (Google Ventures)ILIllumina VenturesMEMenlo VenturesSOSoftBank Vision FundVEVenrock+2 more

San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.

Co-investorsDEDecheng CapitalALAlexandriaDEDeerfield Management CompanyGVGV (Google Ventures)NANan Fung Life SciencesNONorthpond Ventures

Countable Labs (formerly Enumerix) develops a digital PCR platform that performs genetic analysis with higher sensitivity, precision, and dynamic range than legacy PCR methods.

AI & Machine LearningBiotechDeep TechMedical Devices

Develops novel ocular therapies.

BiotechMorrisville, US

BYBen Yerxa(Executive Officer)inELEric Linsley(Executive Officer)in

BoardEMEd Mathers(Director)inStephen Bloch(Director)inSeth Rudnick(Director)inNeal Fowler(Director)

Co-investorsCACanaan PartnersNENew Enterprise Associates (NEA)PAPappas Capital+N+ND CapitalILIllumina VenturesOMOMX Ventures

Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.

BiotechMedical DevicesSan Diego, US

PTPam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Co-founder and first Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)PTPam Taub, M.D., FACC(Co-founder)

Co-investorsBLBluebird VenturesBRBroadview VenturesLOLongitude CapitalADAdams Street PartnersVEVertex VenturesVEVertex Ventures HC

EQRx was a Cambridge, MA biopharma that aimed to sell lower-priced novel drugs; it was acquired by Revolution Medicines in 2023.

Alexis Borisy(Founder)

Co-investorsANAndreessen HorowitzARArboretum VenturesGVGV (Google Ventures)NENextech InvestBABain CapitalCACasdin Capital+1 more

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical DevicesBrisbane, US

JMJordi Mata-Fink(Chief Executive Officer, Co-Founder)inRTRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)inJordi Mata-Fink, Ph.D.(Chief Executive Officer, Co-Founder)Raman Talwar, M.S.(Chief Technology Officer, Co-Founder)Pat Sharp, Ph.D.(Scientific Founder)

Co-investorsFOForbionVEVersant VenturesANAndreessen HorowitzFEFelicis VenturesGVGV (Google Ventures)

Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.

BiotechCambridge, US

GKGabriel Kwong(Executive Officer)inSBSangeeta BhatiainRBRoopom Banerjee(Executive Officer)in

BoardTGTheresia Gouw(Director)inASAmy Schulman(Director)SLStan Lapidus(Director)in

Co-investorsGRGreatPoint VenturesACAcrew CapitalASAspect VenturesCACatalio Capital ManagementCRCRV (Charles River Ventures)DNDns Capital+7 more

Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.

Cambridge, US

LJLeslie J Williams(Executive Officer, Director)

BoardBenjamin Chen(Director)SMSeiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)SGSteven Gillis(Director)in

Co-investors5A5AM Ventures8V8VCATAtlas VenturePAPanacea VentureTATaiho Ventures, LLCTATakeda Ventures

Comofi Medtech develops healthcare technology, including an AI/AR-based surgical intervention platform for surgical procedures and an NT-Mask, aimed at improving patient outcomes and the safety and efficiency of healthcare practitioners.

AI & Machine LearningHealthtechMedical Devices

Co-investorsJIJITO Angel NetworkCICIIE.COIIIIMA VenturesABAbstract VenturesGEGeneral CatalystLILightspeed Venture Partners

Butterfly Learnings provides developmental and behavioral therapy for children with autism, including speech and behavior support delivered by senior and behavior therapists.

Digital HealthHealthtechWellness & FitnessMumbai, IN

Co-investorsIIIIMA VenturesINInsitorABAbstract VenturesGEGeneral CatalystLILightspeed Venture Partners

Biotech company developing antibodies to treat autoimmune and inflammatory diseases.

Co-investorsALAlpha Wave GlobalARArkin CapitalARArkin Digital HealthJEJeito CapitalMOMonograph Capital PartnersVIViking Global+1 more

HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis.

BiotechMedical Devices

JAJulio Aguirre-Ghiso, Ph.D.(Co-Founder)Steven Gillis, Ph.D.(Chairman & Acting CEO)

Co-investorsMAMagnetic VenturesRARaptor Group6 6 Dimensions CapitalHEHercules Capital, Inc.HIHillhouse Capital

Homeward provides cash offers for home purchases, allowing buyers to make competitive offers without financing contingencies while enabling real estate agents to maintain full commissions.

FintechPropTechAustin, US

Jeff Diehl(Director)Jeffrey Crowe(Director)Srini Palamarthy(Executive Officer)Ben Rubenstein(Director)

BoardTHTim Heyl(Founder)inKSKrishna Srinivasan(Director)in

Co-investorsBRBreyer CapitalEREra VenturesHAHarmony PartnersJAJavelin Venture PartnersLILiveOak VenturesNONorwest Venture Partners+3 more

Homeward Health provides in-home and virtual primary care and care coordination services for Medicare Advantage patients, helping with appointment scheduling, health advocacy, insurance navigation, and access to community resources.

Digital HealthHealthtech

Co-investorsGEGeneral CatalystHUHuman Capital

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)ATArthur Tzianabos(Executive Officer, Director)KPKush Parmar(Director)inRichard Gregory(Director)

Co-investors5A5AM VenturesOUOUP (Osage University Partners)ALAlexandriaDEDeerfield Management CompanyFIFidelity InvestmentsHBHBM Healthcare Investments+5 more

Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.

Li Chen(Founder)

Co-investorsF-F-Prime CapitalVEVenrock6 6 Dimensions CapitalALAlly Bridge GroupBLBlue Pool CapitalEIEight Roads Ventures+2 more

Scalable, high throughput DNA sequencing platforms.

Co-investorsARArtis VenturesHEHemisphere Ventures LLCHEHeran PartnersSPSPRINGROCK VENTURESVEVenrockGEGenesys Capital

ImmusanT works on scientific research into the mechanisms of celiac disease, collaborating with investigators from academic and medical research institutions.

BiotechHealthtechCambridge, US

LWLeslie Williams(Executive Officer, Director)Thomas Daniel(Director)Steven Gillis(Director)Thomas Koestler(Director)

BoardCeclia Gonzalo(Director)Kevin Ferro(Director)

Co-investorsVAVatera Healthcare Partners

Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.

BiotechHealthtechMedical DevicesLake Forest, US

JNJoseph NolaninJNJoe Nolan, MBA(Chief Executive Officer)

Co-investorsAIAIFJDJDRF T1D FundDEDeerfield Management CompanyGOGoldman SachsSASamsung Ventures

Just - Evotec Biologics is a contract development and manufacturing organization (CDMO) providing antibody discovery, process development, and cGMP manufacturing services for antibodies, next-generation biologics, and biosimilars.

Advanced ManufacturingBiotechHealthtechSeattle, US

A biopharmaceutical company developing CAR-T cell therapies for cancer treatment.

BiotechHealthtechMedical DevicesShanghai, CN

Co-investorsACAcorn Pacific VenturesYUYuanBio Venture CapitalSHShiyu CapitalTETemasek

Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.

Co-investorsPIPivotal Life SciencesSOSofinnova VenturesALAlexandriaPUPureTech HealthWEWellcome Trust

Kisbee Therapeutics is a Watertown, Massachusetts biotech/healthtech company founded in 2019 and backed by ARCH Venture Partners.

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Tim Wang(Cofounder)JTJOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DPDAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)Qasim Rizvi(Chief Executive Officer)inJAMES GILBERT(Director)

Co-investorsALAlpha Wave GlobalFLFlagship PioneeringLALAVLGLG Technology VenturesLILilly Asia VenturesBABaillie Gifford+3 more

Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.

Allen Chao(Founder)

Co-investorsAIAisling CapitalMEMESA VERDE VENTURE PARTNERSPRProspect Venture PartnersSCSchooner CapitalALALTITUDE LIFE SCIENCE VENTURESFOFoley Ventures+2 more

LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.

AI & Machine LearningBiotechDeep TechCambridge, US

GLGregory L. Verdine(Executive Officer, Director)GVGregory Verdine, Ph.D.

BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)

Co-investorsGVGV (Google Ventures)RARA CapitalAIAisling CapitalALAlexandriaBEBezos ExpeditionsBLBlue Pool Capital+7 more

Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.

BiotechDeep TechHealthtech

Co-investors+N+ND CapitalILIllumina VenturesLOLongwall Venture Partners LLPM M VenturesOMOMX Ventures

Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale.

BiotechDeep TechMedical DevicesCambridge, GB

Co-investorsILIllumina VenturesPEPerscitus LLP+N+ND CapitalM M VenturesOMOMX Ventures

San Diego, US

Bob Kain(Executive Officer, Director)inDBDawn Barry(Executive Officer)inJoseph C. Beery(Executive Officer, Director)

Co-investorsBABain Capital VenturesF-F-Prime CapitalILIllumina Ventures

Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.

BiotechDeep TechHealthtechMedical DevicesBothell, US

Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHTHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)

Co-investorsFOForesite CapitalVEvenBio Partners8V8VCAXAxial VC

Lyell Immunopharma is a Nasdaq-listed cell therapy developer engineering T cell therapies for solid tumors and blood cancers.

Co-investorsAXAxial VCFOForesite Capital

Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.

Advanced ManufacturingBiotechHealthtechMedical Devices

Co-investorsCRCross Creek AdvisorsPFPfizer Venture InvestmentsSISignet Healthcare PartnersSOSofinnova Ventures